Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess procedural safety and glycemic indices at 6 months in a first-in-human study of duodenal mucosal resurfacing (DMR), a novel, minimally invasive, upper endoscopic procedure involving hydrothermal ablation of the duodenal mucosa, in patients with type 2 diabetes and HbA1c ≥7.5% (58 mmol/mol) on one or more oral antidiabetic agents. RESEARCH DESIGN AND METHODS: Using novel balloon catheters, DMR was conducted on varying lengths of duodenum in anesthetized patients at a single medical center. RESULTS: A total of 39 patients with type 2 diabetes (screening HbA1c 9.5% [80 mmol/mol]; BMI 31 kg/m2) were treated and included in the interim efficacy analysis: 28 had a long duodenal segment ablated (LS; ∼9.3 cm treated) and 11 had a short segment ablated (SS; ∼3.4 cm treated). Overall, DMR was well tolerated with minimal gastrointestinal symptoms postprocedure. Three patients experienced duodenal stenosis treated successfully by balloon dilation. HbA1c was reduced by 1.2% at 6 months in the full cohort (P < 0.001). More potent glycemic effects were observed among the LS cohort, who experienced a 2.5% reduction in mean HbA1c at 3 months postprocedure vs. 1.2% in the SS group (P < 0.05) and a 1.4% reduction at 6 months vs. 0.7% in the SS group (P = 0.3). This occurred despite net medication reductions in the LS cohort between 0 and 6 months. Among LS patients with a screening HbA1c of 7.5–10% (58–86 mmol/mol) and on stable antidiabetic medications postprocedure, HbA1c was reduced by 1.8% at 6 months (P < 0.01). CONCLUSIONS: Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability. Long-term safety, efficacy, and durability and possible mechanisms of action require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The intragastric balloon and transpyloric shuttle trials included some persons with T2D, but numbers were inadequate to assess safety and efficacy in those with T2D.787–789”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“Some endoscopic and orally delivered devices have been approved by the FDA for treatment of obesity, including hydrogel capsules,786 intragastric balloon systems,787–788 a transpyloric shuttle that blocks gastric emptying,789 and gastric aspiration therapy that evacuates partial gastric contents following meals via a variation of a percutaneous endoscopic gastrostomy tube.790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“While weight loss following DMR is modest (~2.5 kg at six months), significant metabolic benefits have been reported.”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
In the citing paper
“Improvements in glycemic control, including a 1.2% reduction in HbA1c at six months, have been observed, particularly following long-segment ablation [92].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Despite a wide choice of pharmacological interventions, many patients do not achieve adequate control of hyperglycemia (1).”
BackgroundRubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Self-citationRubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
Self-citationRubino, F., & Marescaux, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000102989.54824.fc · Cited by 617
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396 · cited 1×
“Duodenal biopsy from humans with diabetes also shows hypertrophy, thickening, and an overgrowth of entero-endocrine cell types (22).”
BackgroundLaferrère, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R. D., Wenner, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002043 · Cited by 384
Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Jacobsen, S. H., Serup, A. K., Albers, P. H., Hansen, D. L., Worm, D., Naver, L., Kristiansen, V. B., et al. (2014) · Diabetes · doi:10.2337/db13-1307 · Cited by 254
Breen, D. M., Rasmussen, B. A., Kokorovic, A., Wang, R., Cheung, G. W. C., & Lam, T. K. T. (2012) · Nature Medicine · doi:10.1038/nm.2745 · Cited by 209 · cited 1×
“This suggests a potential effect on hepatic glucose production, possibly through an insulin-sensitizing mechanism, in line with previous observations in duodenal-jejunal bypass (17) and Roux-en-Y gastric bypass surgery (18–20).”
Result
Cited by
Items 201–219 of 219
Jin, T., Zhou, Y., Sun, P., Ding, L., Xu, L., Ji, F., & Jin, X. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0009
PIMA facie evidence for endoscopic therapy in type 2 diabetes
Siau, K. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103274
The Role of Endobariatrics in a Bariatric Surgery Program
VanderWel, B. (2025) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161251354940
The Role of Bariatric Surgery in the Treatment of Obese Women with Polycystic Ovary Syndrome
Söylemez, E. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1011572 · Cited by 1
A moonshot for diabetes and obesity
Lee, L. S., Caplan, J., & Rajagopalan, H. (2025) · iGIE · doi:10.1016/j.igie.2025.09.013
Self-citationMeiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Figshare · doi:10.6084/m9.figshare.21191998
Maskill, V. R. (2021) · Otago University Research Archive (University of Otago)
Sustained Glycaemic Improvement After Duodenal Mucosal Resurfacing in Type 2 Diabetes
Rami, A., Alsayes, Z., Kettaneh, K., Mohammad, R., Obeidat, S., & Draghmeh, S. (2025) · Academic Medicine & Surgery · doi:10.62186/001c.145731
Duodenal mucosal intervention in the management of MASLD and type 2 diabetes
Saeed, Z., Liu, B., Yousaf, M., & Liu, W. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02023-w · Cited by 1
“%) and liver fat levels on MRI in contrastto lifestyle intervention alone [9].”
Masood, M., Sharaiha, R. Z., Siddique, A., Deal, S. B., & Kozarek, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020345
“Rajagopalan et al. demonstrated that a single session of DMR resulted in clinically significant improvement in hyperglycemia in patients with type 2 diabetes mellitus with acceptable safety and tolerability [40].”
Endoscopic small bowel therapies for type 2 diabetes
Patel, R., Naseem, Z., Gattu, P., Firkins, S., & Simons-Linares, R. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70111
“17 6 ‐ month follow ‐ up, with a mean ± SD HgbA1C reduction of 1.2% ± 0.3%.”
InfluentialEndoscopy for Metabolic Diseases
Matteo, M. V., Hussein, J. K. I., Carlino, G., Bove, V., Pontecorvi, V., Gualtieri, L., Siena, M. D., Vincenzo, M. D., Verme, L. Z. D., Salvi, D., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082832
“…received either shorter or longer duodenal ablation lengths demonstrate a length-dependent response, whereby patients undergoing longer segments of duodenal ablation ( ≥ 9 cm) exhibited significantly greater reductions in FPG and HbA1c than those treated with shorter ablation lengths ( 6 cm) [48].”
InfluentialIntragastric Balloon and Other Primary Endoscopic Therapies
Olavarria, O. A., Crawford, L. S., John, K., Shah, S. K., & Wilson, E. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_47
Endoscopic bariatric and metabolic therapies
Khurana, A. T., Nadeem, A., & Firkins, S. A. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.005
Suangburanakul, N., Siranart, N., Pajareya, P., Surasaksrisakul, N., & Steinway, S. N. (2026) · Research Square · doi:10.21203/rs.3.rs-10491029/v1
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
New avenues in metabolic disease treatment: duodenal mucosal resurfacing and gene therapy
Dias, C., Patel, S., Gaglani, T., & Thosani, N. C. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101482
Metadata
- Authors
- Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P.
- Affiliations
- Fractyl (United States) (US)
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- King's College London (GB)
- Catholic University of Rome, Rome, Italy
- CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
- Gastro Obeso Center, São Paulo, Brazil
- Corresponding author
- Rajagopalan, Harith
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-12
- Volume
- 39
- Issue
- 12
- Pages
- 2254-2261
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514895276
- Cited by
- 216
- References
- 35
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 17 · 2023: 14 · 2022: 17 · 2021: 25 · 2020: 34 · 2019: 24 · 2018: 20 · 2017: 32 · 2016: 2
- FWCI
- 26.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Fractyl Laboratories, Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- duodenal mucosal resurfacing, type 2 diabetes, HbA1c reduction, glycemic control, balloon catheter, duodenal stenosis, antidiabetic medication reduction, procedural safety, first-in-human study
- MeSH terms
- Adult, Aged, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Pilot Projects, Endoscopy, Gastrointestinal, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.